Abbott Laboratories (NYSE:ABT) Shorts Rose By 9.38% As Of Dec 8, 2018

Abbott Laboratories (NYSE:ABT) Corporate Logo

During 2018 Q2 the big money sentiment increased to 0.86. That’s change of 0.03, from 2018Q1’s 0.83. 41 investors sold all, 583 reduced holdings as Abbott Laboratories ratio is positive. 420 grew holdings while 117 funds acquired holdings. Funds hold 1.23 billion shares thus 0.63% more from 2018Q1’s 1.22 billion shares.
Fort Point Capital Prtnrs Limited Liability Co holds 4,649 shs or 0.1% of its capital. Redmile Grp Inc Llc accumulated 449,300 shs. City Holding Co, West Virginia-based fund reported 50,654 shs. Financial Bank Of The West holds 0.41% or 54,311 shs. Long Road Investment Counsel Ltd Liability Com accumulated 12,644 shs or 0.55% of the stock. Miles Cap Inc stated it has 0.14% in Abbott Laboratories (NYSE:ABT). Wesbanco Comml Bank invested in 0.52% or 164,688 shs. 122,374 are held by First Midwest Commercial Bank Tru Division. Massachusetts-based State Street has invested 0.34% in Abbott Laboratories (NYSE:ABT). Green Valley Investors Ltd Liability Co has 1.83 million shs. Silvercrest Asset Mgmt Group has 2.29M shs. Cincinnati holds 0.62% or 237,800 shs in its capital. Acg Wealth has 8,603 shs for 0.08% of their capital. The Pennsylvania-based Armstrong Henry H Associate Inc has invested 0.32% in Abbott Laboratories (NYSE:ABT). Moreover, Two Sigma Ltd has 0.01% invested in Abbott Laboratories (NYSE:ABT) for 35,813 shs.

Abbott Laboratories had 13 selling transactions and 0 buys since July 21, 2018. This’s net activity of $30.08 million. 9,097 shs were sold by LANE ANDREW H, worth $610,513. On Monday, July 23 Bracken Sharon J also sold $16,369 worth of Abbott Laboratories (NYSE:ABT). 58,200 Abbott Laboratories (NYSE:ABT) shs with value of $4.00M were sold by Blaser Brian J. On Friday, September 28 Shares for $366,957 were sold by Salvadori Daniel Gesua Sive. 64,268 shs valued at $4.30 million were sold by Contreras Jaime on Wednesday, August 29. On Wednesday, November 28 WHITE MILES D sold $10.30M worth of Abbott Laboratories (NYSE:ABT) or 142,341 shs.

Abbott Laboratories (NYSE:ABT) had an increase of its shorted shares by 9.38%. It was issued in December by FINRA the 12.75M shorted shares on ABT. The up change of 9.38% from 11.65M shares was reported. Abbott Laboratories (NYSE:ABT) has 4.43 million shares average volume. It’ll cost 3 days for ABT to recover its previous position.

ABT is touching $69.95 during the last trading session, after decreased 2.22%.Abbott Laboratories is uptrending after having risen 28.17% since December 8, 2017. ABT has 7.95M volume or 16.84% up from normal. The stock outperformed the S&P 500 by 12.55%.

Abbott Laboratories manufactures and sells health care products worldwide.The firm is worth $122.86 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.The P/E ratio is 140.74. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

In total 10 analysts cover Abbott Laboratories (NYSE:ABT). “Buy” rating has 10, “Sell” are 0, while 0 are “Hold”. (NYSE:ABT) has 100% bullish analysts. 11 are the (NYSE:ABT)’s ratings reports on Dec 8, 2018 according to StockzIntelligence Inc. On Thursday, October 18 the firm has “Outperform” rating given by Raymond James. In Monday, September 24 report Raymond James maintained the stock with “Outperform” rating. The stock rating was maintained by JP Morgan with “Overweight” on Monday, October 8. On Friday, November 30 the rating was upgraded by Goldman Sachs to “Buy”. On Monday, September 24 the firm has “Outperform” rating given by Wells Fargo. On Thursday, October 11 Morgan Stanley maintained the shares of ABT in report with “Overweight” rating. On Thursday, July 19 the firm has “Buy” rating given by Stifel Nicolaus.

For more Abbott Laboratories (NYSE:ABT) news posted recently go to: Fool.com, Fool.com, Businesswire.com, Seekingalpha.com or Forbes.com. The titles are as follows: “Stock Market Power Rankings: Microsoft Parties Like Its 2002 – The Motley Fool” posted on December 02, 2018, “Stock Market Power Rankings: Save Us, Amazon – The Motley Fool” on November 25, 2018, “Know Labs Announces Laboratory Comparison Tests of Its UBAND Non-Invasive Blood Glucose Technology and Abbott Labs FreeStyle Libre – Business Wire” with a publish date: December 06, 2018, “FDA issues new draft guidance for blood glucose monitors – Seeking Alpha” and the last “Expect Diagnostics And Medical Devices Business To Drive Abbott’s Near-Term Earnings Growth – Forbes” with publication date: November 28, 2018.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.